These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20386102)

  • 1. Treatment of benign essential blepharospasm with finasteride: a case report.
    Bortolato M; Cannas A; Solla P; Puligheddu M; Muroni A; Marrosu F
    Clin Neuropharmacol; 2010 Jul; 33(4):207-8. PubMed ID: 20386102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride attenuates pathological gambling in patients with Parkinson disease.
    Bortolato M; Cannas A; Solla P; Bini V; Puligheddu M; Marrosu F
    J Clin Psychopharmacol; 2012 Jun; 32(3):424-5. PubMed ID: 22534502
    [No Abstract]   [Full Text] [Related]  

  • 3. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA
    East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based urology in practice: composite endpoints.
    Lavallée LT; Dahm P; Breau RH
    BJU Int; 2010 Sep; 106(5):610-2. PubMed ID: 20553252
    [No Abstract]   [Full Text] [Related]  

  • 5. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H; Chen J; Braf Z
    Harefuah; 1993 Dec; 125(12):453-6, 496. PubMed ID: 7509305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Finasteride in prolonged therapy of patients with benign prostatic hyperplasia].
    Mazo EB
    Urologiia; 2001; (3):20-2. PubMed ID: 11505535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blepharospasm and apraxia of eyelid opening associated with anti-Hu paraneoplastic antibodies: a case report.
    Choe CH; Gausas RE
    Ophthalmology; 2012 Apr; 119(4):865-8. PubMed ID: 22264884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
    Alcántara-Montero A; Brenes-Bermúdez FJ
    Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
    [No Abstract]   [Full Text] [Related]  

  • 10. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-oriented approach to botulinum toxin use.
    Jankovic J
    Toxicon; 2009 Oct; 54(5):614-23. PubMed ID: 19073203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign essential blepharospasm.
    Malinovsky V
    J Am Optom Assoc; 1987 Aug; 58(8):646-51. PubMed ID: 3624758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
    Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary spastic paraplegia associated with dopa-responsive parkinsonism.
    Micheli F; Cersósimo MG; Zúñiga Ramírez C
    Mov Disord; 2006 May; 21(5):716-7. PubMed ID: 16463348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
    Ekman P
    Arch Esp Urol; 1994 Nov; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finasteride: middle-age cure-all for alopecia and benign prostatic hyperplasia?
    Federman DG
    Mayo Clin Proc; 2006 Feb; 81(2):267; author reply 267-8. PubMed ID: 16471089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.